New immunotherapy may let some women skip surgery for endometrial cancer
NCT ID NCT07369986
First seen Jan 29, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) can shrink or eliminate tumors in women with a specific type of endometrial cancer (mismatch repair-deficient). The goal is to see if these drugs can be an alternative to surgery. About 30 women with early-stage, surgically removable cancer will receive the treatment and be monitored for complete response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.